Mahi Drugs Private Limited appointed Cost Auditors for the year 2026-27 and Mr. Vincent P Asrao as Nominee Director.

Ha eos -;'J~" August 5, 2026 BSE Limited, National stock Exchange of India Limited, listing Department, P J Towers, listing Department, "Exchange Plaza", Dalal street, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 001. Mumbai -400 051. Scrip Code: 540679 Trading S mbol: HALEOSLABS SUB: UPDATE ON MATERIAL SUBSIDIARY_ Ref: Reg_ 30 (9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, With reference to the above-cited subject, we hereby inform you that the Board of Directors of Mis Mahi Drugs Private limited, a material subsidiary of the Company, at its meeting held today, i.e., August 5, 2026, has, inter alia, approved the following: 1) Appointment of Cost Auditors for the year 2026·27. Annapragada & Co. [firm resignation no. 0060311 appointed as Cost Auditors of the Subsidiary Company for the year 2026-27 pursuant to the provisions Of Section 148 of the Companies Act, 2013 read with Rule 14 and other applicable rules of the Companies (Audit and Auditors) Rules, 2014. 2) Appointment of Nominee Director. Mr. Vincent P. Asaro (DIN: 11827706) have been appOinted as the Nominee Director of Subsidiary Company as nominated by ChemWerth Inc., w.e.f. August 5, 2026, in place of Mr. M. Madhu Rao, who shall cease to be Nominee Director of the Subsidiary company with effect from the same date. The above information is also available on the website of the Company www.haleoslabs.com Please take the same on record and suitably disseminate to all concerned. For Haleos Labs Limited (Formerly SMS Lifesciences India Limited) Registered & Corporate Office: Plot No. 19-111, Road No. 71, Opp. Bharatiya Vidya Bhavan Public School, Jubilee Hills, Hyderabad -500 096, Telangana, India. Tel: +91-40-662888881 CIN -L74930TG2006PLC050223I info@haleoslabscom I www.haleoslabscom conti ... Appointment of Cost Auditors: particulars Information Name of the Auditor and Firm Annapragada & Co. Registration Number (FRN) (Formerly known as Harshitha Annapragada & Co.") IFRN: 0060311 Reason for change (reapPointment) APpointed as Cost Auditors of the company. APpointed for the financial year 2026-27. Date of reapPointment & term of Appointment in the Board Meeting held on 05.08.2026 and the remuneration shall be reappointment subject to ratification of shareholders in the next Annual General Meeting. Annapragada & Co. (Formerly known as "Harshitha Annapragada & Co."), is a firm of Cost Accountants with good analytical and results driven with good experience in developing and implementing cost account system and analysing cost trends. The firm has experience in the field of Cost Audits, Finance, Forecasting and process Brief Profile improvement. Dedicated Cost Accountant with good experience providing accounting support to various operating groups and manufacturing plants. Good knowledge of relevant government regulations, internal controls, cost accounting methods, and cost modelling tools and other methods. Disclosure of Relationship between Not Applicable Directors Appointment of Nominee Director: particulars Information Name of the Director Mr. Vincent P. Asaro Director IdentiFication Number (DIN) 11827706 NationalitY US Citizen Mr. Asaro is a Certified Public Accountant (CPA) and holds an MBA In Finance from the University of Connecticut and a Bachelor of Science In Accounting from Providence college. He has also completed executive education at Harvard Business School. Education Recognized for his strategic leadership and financial acumen, he is committed to advancing innovation, expanding global partnerships, and strengthening pharmaceutical supply chains to support the development and commercialization of high-Quality generic APls. He Is the President of ChemWerth Inc., a leading global developer and supplier of Active Pharmaceutical Ingredients (APls) to regulated pharmaceutical markets worldwide. With over 35 years of experience in finance, corporate strategy, business development, and pharmaceutical operations, he has played a pivotal role In driving ChemWerth's growth and strengthening its global presence. Prior to his appOintment as President, Mr. Asaro Working Experience served as the Chief Financial Officer of ChemWerth Inc. since 2009, where he led the company's financial strategy, operational excellence, and business expansion initiatives. Earlier in his career, he held finance and leadership positions with Deloltte & Touche and Bayer, gaining extensive expertise in accounting, auditing, internal controls, and corporate finance. He also serves on the Board of Directors of Bedoukian Research, Inc. Relationship between Directors Not Applicable Inter-se ******** Page 2 of2